Long‐term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70309 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Jin-Hua Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kunming Children's Hospital, The Affiliated Children's Hospital of Kunming Medical University, Kunming Medical University, …. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Receptors, Thrombopoietin, Hydrazines, Benzoates. Die Arbeit nennt 25 Literaturangaben. Gefördert von: the Clinical Medicine Center Research Project, The Yunnan Province's "High-level Talent Training Support Program - Specialization for Renowned Doctors".
Abstract (Originalsprache)
Immune thrombocytopenia (ITP) is an autoimmune disorder that occurs in children and adults, and it is characterized by a reduced platelet count. Hetrombopag, a novel thrombopoietin receptor agonist (TPO‐RA) for second‐line ITP treatment, lacks thorough efficacy and safety evaluation in paediatric patients. In this study, we assessed complete response (CR), response (R), overall response (OR), no response (NR), durable response (DR), relapse and treatment‐free response (TFR) rates in 93 paediatric ITP patients who were treated with hetrombopag. The results demonstrated that the CR rate, R rate, OR rate, NR rate, DR rate, relapse rate and TFR rate were 61.3%, 15.1%, 76.3%, 23.7%, 76.1%, 26.8% and 52.1% respectively. Patients with newly diagnosed ITP exhibited a higher TFR rate than those with persistent or chronic ITP. Furthermore, among the nine patients who switched from other TPO‐RAs, seven patients achieved OR during initial treatment, including three patients who achieved CR and four patients who achieved R. The overall incidence of adverse events was 37.6%, with no serious adverse events reported. Our findings highlight that hetrombopag is both safe and effective in paediatric patients and may serve as a viable option for patients for whom first‐line therapy fails.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Kunming Children's Hospital, The Affiliated Children's Hospital of Kunming Medical University, Kunming Medical University, Kunming, China.
- Medical Faculty, Kunming University of Science and Technology, Kunming, China.
ORCID-Profile: Ti-Long Huang, Xian-Wen Zhang
Förderung
- the Clinical Medicine Center Research Project
- The Yunnan Province's "High-level Talent Training Support Program - Specialization for Renowned Doctors"
Zitieren
APA
Wang, J. H., Yang, Q., Duan, S. Q., Yang, L., Zhou, Y., Fang, C. L., Xiao, Z. G., Yang, C. H., Xiong, Y. C., Tian, X., Huang, T. L., & Zhang, X. W. (2026). Long‐term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia. British Journal of Haematology. https://doi.org/10.1111/bjh.70309
Vancouver
Wang JH, Yang Q, Duan SQ, Yang L, Zhou Y, Fang CL, et al. Long‐term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia. British Journal of Haematology. 2026. doi:10.1111/bjh.70309
BibTeX
@article{Wang2026,
author = {Wang, Jin-Hua and Yang, Qing and Duan, Shao-Qin and Yang, Li and Zhou, Yan and Fang, Chun-Lian and Xiao, Zu-Gang and Yang, Chun-Hui and Xiong, Yong-Chao and Tian, Xin and Huang, Ti-Long and Zhang, Xian-Wen},
title = {Long‐term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70309}
}
EUVIMED